Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

33.59 -0.10 (-0.29%)
Streaming Delayed Price Updated: 10:08 AM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Pfizer Was First In Treating This Heart Disease. Why BridgeBio Could Be Better.
The companies are expected to compete in a genetic heart disease beginning in late 2024. 
Via Investor's Business Daily
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Inc. (NASDAQ: BBIO) is a Stock Spotlight on 8/18
Via Investor Brand Network
4 Analysts Have This to Say About BridgeBio Pharma
Via Benzinga
Expert Ratings for BridgeBio Pharma
Via Benzinga
Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It?
Its potential upcoming drug launch might not be enough. 
Via The Motley Fool
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
7 A-Rated Stocks for Your August Buy List
August is shaping up to be a great month for the stock market. Now you just need to make sure you own these A-rated stocks. 
Via InvestorPlace
BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Could This Stock Be the Next Biotech Buyout?
A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next. 
Via The Motley Fool
Why Shares of BridgeBio Pharma Skyrocketed This Week
The biotech company saw strong results in a phase 3 trial. 
Via The Motley Fool
Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review
But all the major indexes are at or near 15-month highs. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023
Via Benzinga
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Crude Oil Falls; GreenPower Motor Company Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 0.25% on Monday. The Dow traded up 0.25% to 34,596.04 while the NASDAQ rose 0.92% to 14,243.64. The S&P 500, also rose,... 
Via Benzinga
Playbook Revisited As UNH Beat Could Help Sagging Healthcare Stocks
Last week saw a broadening of the rally as many top sectors were up over 3%. But healthcare was among the laggards up only 0.7%. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
BridgeBio (NASDAQ: BBIO) Announces Exceptionally Positive Outcomes in Phase 3 Study of Acoramidis
BridgeBio Pharma (NASDAQ: BBIO), a leading biopharmaceutical company, announced significant outcomes from the ATTRibute-CM, their Phase 3 study of acoramidis, 
Via Spotlight Growth
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived... 
Via Benzinga
Nasdaq Gains 100 Points; Guaranty Bancshares Posts Upbeat Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Monday. The Dow traded up 0.19% to 34,574.01 while the NASDAQ rose 0.71% to 14,214.50. The S&P... 
Via Benzinga
Why Are Telecom Stocks Down Today?
Telecom stocks aren't doing so how on Monday after several players in the space were hit by downgrades and lowered price targets from Citi. 
Via InvestorPlace
BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease
The companies are working on treatments for a leading cause of heart failure. 
Via Investor's Business Daily
BridgeBio Pharma Inc. (NASDAQ: BBIO) Records 52-Week High Monday Morning
Via Investor Brand Network
Why Is BridgeBio (BBIO) Stock Up 63% Today?
BridgeBio Pharma (BBIO) stock is climbing higher on Monday as investors react to results from a recent Phase 3 clinical trial. 
Via InvestorPlace
US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July
U.S. stocks traded slightly higher this morning, with the Dow Jones moving higher by around 20 points on Monday. Following the market opening Monday, the Dow traded up 0.06% to 34,529.57 while the... 
Via Benzinga
You Can't Afford to Miss Monday's 2 Nasdaq Biotech Stock Movers
Big gains are afoot even as the markets prepare for a flat open. 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.